Abstract
The PT-domain of Polyketide synthase A (PksA) is crucial product template that controls the aldol cyclization and aromatization to create polyketide precursor. The precursor leads to biosynthesis of aflatoxin secondary metabolites. Being carcinogenic in nature of these secondary metabolic, efforts have been made to explore novel inhibitors targeting the PT-domain of PksA. Previously, [6]-gingerol reported as a prospective inhibitor for the inhibition for aflatoxin biosynthesis, but some of its derivatives such as (S)- [8]-gingerol, 9-Hydroxy-[6]-gingerol, 9-gingerol, 5-O-methyl-[9]-gingerol, methyl-6-gingerol, and [5]-gingerol exhibited better binding affinity. Notably, Leu1508, Asn1554, and Asn1568, are the key amino acid residues that are involved in stabilizing ligand-protein interaction. The study explores the understanding to develop new approach to create novel drug against the PT-domain to restrict the aflatoxin biosynthesis at initiation. However, a detailed in vivo study is required to further evaluation at in vivo stage.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: IP International Journal of Medical Microbiology and Tropical Diseases
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.